UBI集團訊息
愛滋病「每日用藥」治療模式，可能因一篇台灣研究而改變
UB-421抗體不僅阻止愛滋病毒感染新細胞，它似乎也調整了受試者的免疫細胞，使他們能更容易地擊退病毒。
TAG :愛滋病治療單株抗體UB-421
-
-
View More 
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infectionUBI集團訊息United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
A Multicenter, Single-Arm, 24-Week Study of UB-421 in Combination with Optimized Background Therapy (OBT) Regimen in Patients with Multi-Drug Resistant (MDR) HIV-1 Infection. -
View More 
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected PatientsUBI集團訊息United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
IND approval from China NMPA to conduct a multi-nation, multi-center phase 3 clinical trial with UB-421 substitution monotherapy -
View More 
聯生藥治療愛滋病抗體新藥UB-421獲中國國家藥品監督管理局 核准多國多中心臨床3期試驗UBI集團訊息聯生藥治療愛滋病抗體新藥UB-421獲中國國家藥品監督管理局 核准多國多中心臨床3期試驗
治療愛滋病單株抗體新藥UB-421規劃在台灣、泰國與中國三個地區執行之多國多中心臨床3期試驗 -
View More 
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption (N Engl J Med 2019; 380:1535-1545)UBI集團訊息Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption (N Engl J Med 2019; 380:1535-1545)
It is possible that monotherapy with UB-421 could induce sustained virologic suppression without induction of resistance in HIV-infected persons -
View More 
Novel antibody may suppress HIV for up to four months (NIH News Releases)UBI集團訊息Novel antibody may suppress HIV for up to four months (NIH News Releases)
NIH researchers, international collaborators report results of small, open-label study -
-
View More 
美國時代雜誌對新英格蘭醫學期刊4月18日週刊發表之聯生藥UB-421突破性愛滋病臨床試驗結果相關報導UBI集團訊息美國時代雜誌對新英格蘭醫學期刊4月18日週刊發表之聯生藥UB-421突破性愛滋病臨床試驗結果相關報導
In a new study published in the NEJM, researchers at Taiwan-based UBP report encouraging results with a single injection that seems to stymie HIV as well as daily pill regimens. -
View More 
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of MedicineUBI集團訊息United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
United BioPharma’s novel antibody UB-421 suppresses HIV without eliciting resistance -
View More 
聯生藥治療愛滋病抗體新藥 UB-421 臨床 II 期試驗結果 榮獲刊登於新英格蘭醫學期刊UBI集團訊息聯生藥治療愛滋病抗體新藥 UB-421 臨床 II 期試驗結果 榮獲刊登於新英格蘭醫學期刊
「Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption」榮獲刊登於最新一期的NEJM。 -
View More 
United BioPharma received approval of the multi-nation, multi-center phase 3 IND from Thailand FDA for UB-421 in HAART substitution trialUBI集團訊息United BioPharma received approval of the multi-nation, multi-center phase 3 IND from Thailand FDA for UB-421 in HAART substitution trial
The approval from Thailand FDA an IND application for a multi-nation, multi-center, Phase III clinical trial with UB-421 -
View More 
聯生藥愛滋病抗體新藥UB-421多國多中心三期臨床試驗獲泰國FDA核准進行UBI集團訊息聯生藥愛滋病抗體新藥UB-421多國多中心三期臨床試驗獲泰國FDA核准進行
UB-421規劃在台灣、中國與泰國三個地區執行之多國多中心HAART取代性療法第三期臨床試驗
-
-
View More 
我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！ -
View More 
我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力–我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力– -
View More 
我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏
